ganodermadiol profile

ganodermadiol: isolated from Ganoderma lucidum; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	13934286
CHEMBL ID	240972
CHEBI ID	142261
SCHEMBL ID	4446384
MeSH ID	M0143581

Synonym
ganodermadiol
ganoderol b
CHEMBL240972
(+)-ganoderol b
(3beta,24e)-lanosta-7,9(11),24-triene-3,26-diol
CHEBI:142261
z99bbb5wr6 ,
unii-z99bbb5wr6
(3beta,24e)-lanosta-7,9(11),24-trien-3,26-diol
lanosta-7,9(11),24-triene-3,26-diol
lanosta-7,9(11),24-triene-3,26-diol, (3beta,24e)-
bdbm50356918
SCHEMBL4446384
AC-34458
ganodermadiol; ganoderol b
Q65689742
(3s,5r,10s,13r,14r,17r)-17-((e,2r)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta(a)phenanthren-3-ol
(3.beta.,24e)-lanosta-7,9(11),24-triene-3,26-diol
MS-27923
(3s,5r,10s,13r,14r,17r)-17-[(e,2r)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-3-ol
CS-0019546
HY-N2223
DTXSID201045683
AKOS040760130

Role	Description
hepatoprotective agent	Any compound that is able to prevent damage to the liver.
antiviral agent	A substance that destroys or inhibits replication of viruses.
fungal metabolite	Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
3beta-sterol	A sterol in which the hydroxy group at position 3 has beta- configuration.
primary allylic alcohol	An allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to two hydrogens.
tetracyclic triterpenoid	Any triterpenoid consisting of a tetracyclic skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cholinesterase	Homo sapiens (human)	IC50 (µMol)	200.0000	0.0000	1.5599	10.0000	AID630340
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	26.7800	0.0000	0.9332	10.0000	AID630339
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cholinesterase	Homo sapiens (human)
learning	Cholinesterase	Homo sapiens (human)
negative regulation of cell population proliferation	Cholinesterase	Homo sapiens (human)
neuroblast differentiation	Cholinesterase	Homo sapiens (human)
peptide hormone processing	Cholinesterase	Homo sapiens (human)
response to alkaloid	Cholinesterase	Homo sapiens (human)
cocaine metabolic process	Cholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission	Cholinesterase	Homo sapiens (human)
response to glucocorticoid	Cholinesterase	Homo sapiens (human)
response to folic acid	Cholinesterase	Homo sapiens (human)
choline metabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amyloid-beta binding	Cholinesterase	Homo sapiens (human)
catalytic activity	Cholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Cholinesterase	Homo sapiens (human)
cholinesterase activity	Cholinesterase	Homo sapiens (human)
protein binding	Cholinesterase	Homo sapiens (human)
hydrolase activity, acting on ester bonds	Cholinesterase	Homo sapiens (human)
enzyme binding	Cholinesterase	Homo sapiens (human)
choline binding	Cholinesterase	Homo sapiens (human)
identical protein binding	Cholinesterase	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Cholinesterase	Homo sapiens (human)
nuclear envelope lumen	Cholinesterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cholinesterase	Homo sapiens (human)
blood microparticle	Cholinesterase	Homo sapiens (human)
plasma membrane	Cholinesterase	Homo sapiens (human)
extracellular space	Cholinesterase	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID630340	Inhibition of BChE assessed as hydrolysis of butrylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID307899	Inhibition of steroid 5-alpha-reductase activity in Sprague-Dawley rat liver microsomes at 113 uM after 10 mins	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID307902	Growth inhibition of human LNCaP cells after 3 days	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID1313604	Cytotoxicity against LPS-induced mouse BV2 cells assessed as cell viability after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Lanostane triterpenoids from Ganoderma curtisii and their NO production inhibitory activities of LPS-induced microglia.
AID307906	Inhibition of testosterone induced ventral prostate growth in Sprague-Dawley rat at 0.001 mg/kg/day, po after 7 days	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID1235937	Inhibition of alpha-glucosidase (unknown origin)	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID307905	Inhibition of testosterone induced ventral prostate growth in Sprague-Dawley rat at 0.1 mg/kg/day, po after 7 days	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID779722	Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method	2013	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21	Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID307901	Displacement of dihydrotestosterone from human recombinant AR ligand binding domain at 15 uM by fluorescence polarization method	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID307904	Growth inhibition of human LNCaP cells in presence of dihydrotestosterone after 3 days	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID1313603	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Lanostane triterpenoids from Ganoderma curtisii and their NO production inhibitory activities of LPS-induced microglia.
AID779721	Ratio of acarbose IC50 to compound IC50 for alpha-glucosidase (unknown origin)	2013	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21	Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID630339	Inhibition of AChE assessed as hydrolysis of acetylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum.
AID711441	Cytotoxicity against human HeLa cells	2012	Journal of natural products, Nov-26, Volume: 75, Issue:11	Lanostanoids from fungi: a group of potential anticancer compounds.
AID307903	Growth inhibition of human LNCaP cells in presence of testosterone after 3 days	2007	Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14	The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum.
AID353560	Antiproliferative activity against human PC3 cells after 3 days by NR assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (18.18)	29.6817
2010's	9 (81.82)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
tert-butylhydroperoxide tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes.	2.08	1	alkyl hydroperoxide	antibacterial agent; oxidising agent
Berberine chloride (TN) [no description available]	2.06	1	organic molecular entity
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.11	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.17	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.44	2	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
atorvastatin [no description available]	2.11	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
eburicoic acid eburicoic acid: structure	3.17	1
10-hydroxycamptothecin [no description available]	3.17	1	pyranoindolizinoquinoline
lanosterol [no description available]	2.82	3	14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid	bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
acarbose [no description available]	2.5	2	amino cyclitol; glycoside
ergosterol [no description available]	2.15	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
ganoderic acid a [no description available]	3.58	2	triterpenoid
ganoderiol f ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source	4.1	4	triterpenoid
Ganodermanontriol [no description available]	4.29	5	triterpenoid	metabolite
quercetin [no description available]	2.13	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
alpha-linolenic acid linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.	2.05	1	linolenic acid; omega-3 fatty acid	micronutrient; mouse metabolite; nutraceutical
ergosterol-5,8-peroxide ergosterol-5,8-peroxide: also inhibits sulfatase; isolated from fungus Cercospora kikuchii; structure given in first source. ergosterol peroxide : An ergostanoid that is ergosta-6,22-dien-3-ol with a peroxy group between positions 5 and 8 (the 3beta,5alpha,8alpha,22E stereoisomer). Isolated from Ganoderma lucidum and Cordyceps sinensis, it exhibits antimycobacterial, trypanocidal and antineoplastic activities.	2.15	1	3beta-sterol; ergostanoid; organic peroxide; phytosterols	antimycobacterial drug; antineoplastic agent; metabolite; trypanocidal drug
poricoic acid g poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.	3.17	1	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite
polyporenic acid c [no description available]	3.17	1
trametenolic acid b trametenolic acid B: from Trametes lactinea; structure in first source	3.17	1	triterpenoid
lucidenic acid a lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source	3.57	2	triterpenoid
lucidenic acid n lucidenic acid N: from the dried fruiting bodies of Ganoderma lucidum (polyporaceae); structure in first source. lucidenic acid N : A tetracyclic triterpenoid that is 25,26,27-trinorlanost-8-en-24-oic acid substituted by hydroxy groups at positions 3 and 7 and oxo groups at positions 11 and 15 respectively (the 3beta,5alpha,7beta stereoisomer). Isolated from the fruiting bodies of Ganoderma lucidum, it exhibits cytotoxicity against tumour cells.	2.06	1	cyclic terpene ketone; dioxo monocarboxylic acid; secondary alcohol; tetracyclic triterpenoid	antineoplastic agent; EC 3.1.1.8 (cholinesterase) inhibitor; metabolite
ganoderic acid t ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source	3.61	2
ganoderic acid f ganoderic acid F: isolated from Ganoderma lucidum; structure in first source	3.6	2	triterpenoid
inotodiol inotodiol: structure in first source	3.17	1
3,7-dioxolanosta-8,24-dien-26-oic acid [no description available]	3.86	3
ganoderic acid c2 ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source	3.58	2	triterpenoid
ganoderic acid y ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source	3.87	3	triterpenoid
7-oxo-ganoderic acid z 7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source	3.59	2

ganodermadiol

Description

Cross-References

Synonyms (24)

Roles (3)

Drug Classes (3)

Protein Targets (2)

Inhibition Measurements

Biological Processes (25)

Molecular Functions (15)

Ceullar Components (16)

Bioassays (16)

Research

Studies (11)

Market Indicators

Research Demand Index: 12.58

Study Types

ganodermadiol

Description

Cross-References

Synonyms (24)

Roles (3)

Drug Classes (3)

Protein Targets (2)

Inhibition Measurements

Biological Processes (25)

Molecular Functions (15)

Ceullar Components (16)

Bioassays (16)

Research

Studies (11)

Market Indicators

Research Demand Index: 12.58

Study Types

Related Drugs (29)

Related Conditions (0)